CancerVisit

1.8K posts

CancerVisit banner
CancerVisit

CancerVisit

@CancerVisit_com

🎗 One stop shop for Cancer information for patients, families, and healthcare providers. #nutrition #wellbeing #cancercare

Austin, TX Sumali Aralık 2020
4.3K Sinusundan3.8K Mga Tagasunod
CancerVisit nag-retweet
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
💡 Cancer doesn’t recognize borders—neither should knowledge. Grateful to launch a global oncology news platform with @oncodaily through @MedNewsWeek —uniting physicians, researchers, pharma leaders, and patients around one shared mission. One platform. Global voices. Faster impact. Looking forward to serving a world wide audience w/ @YLeyfman 👉 linkedin.com/posts/oncodail… @GevTamamyan @YJanjigianMD @JasmineKambojMD @curijoey @drenriquegrande @DrYukselUrun @yekeduz_emre @crisbergerot @PGrivasMDPhD @oncodaily
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 tweet media
English
0
6
9
556
CancerVisit nag-retweet
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
💡 18 years ago, I met Dr. Lawrence Einhorn. My 1st mentor. He is an elite clinician. Trial pioneer. Exceptional human. At @ASCO #GU26 we had our annual @OncLive Fellows Forum. ⭐️Loved hearing the trainees present their cancer research and the impact their mentors had on their careers. Mentorship doesn’t just build careers. It builds the future of cancer care. 🔬✨ Grateful to see you at #GU26 Dr. Einhorn. @NazliDizman @MarcMachaalani @JeffreyYZhong @AksheeBatra @KalantriShreyas @PGrivasMDPhD @montypal @DrChoueiri @neerajaiims @DrRanaMcKay @CaPsurvivorship @TDorffOnc @DrYukselUrun @yekeduz_emre @oncodaily
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 tweet media
English
3
12
43
5.7K
CancerVisit
CancerVisit@CancerVisit_com·
RT @CParkMD: ✌️ PEACE-3 is a true OS-positive trial. Enzalutamide + radium-223 beats enzalutamide alone in bone-dominant mCRPC. ✅ HR 0.76…
English
0
2
0
1
CancerVisit nag-retweet
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
⭐️Progress in oncology is built in moments of shared curiosity. Dinner meeting with Oliver Sartor @sartor_oliver my VISION co-PI and pioneer of PSMA radioligand therapy, discussing how Lutetium-177 is becoming the Model T of radioligand therapy — the first scalable platform for precision systemic radiation in prostate cancer ⚛️🚀 Walking back, we ran into Jonathan Rosenberg (@DrRosenbergMSK ), my EV-301 co-PI and global leader in antibody–drug conjugate development, he discussed Enfortumab vedotin, KEYNOTE-B15, and the convergence of targeted payload therapies 🎯 Not different drugs. Different chapters of the same scientific story 📖 Radioligands. Antibody–drug conjugates. Precision targeting is reshaping cancer therapy 🌍 The future of oncology will be written in better precision development — and in the patients who benefit from it. Where do you think precision oncology goes next? @tompowles1 @DrChoueiri @neerajaiims @PGrivasMDPhD @montypal @shilpaonc @DrYukselUrun @crisbergerot @alantanmd @Stefani19753108 @arnabguonc @Dr_Aggen #serendipity ✨ #GU26 @ASCO @urotoday @oncodaily @OncLive
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 tweet media
English
1
5
16
675
CancerVisit nag-retweet
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
Thank you @DrDanielHeng for stopping by our @ASCO #GU26 poster sessions to review the oncology trainees research and offer career advice. Everyone was very appreciative of your time. @KalantriShreyas @JeffreyYZhong @caseccc @abbylgrier @AJangMD @PBarataMD @JasonBrownMDPhD @HemOncFellows @DrYukselUrun @yekeduz_emre @crisbergerot @NazliDizman @PauloBergerot @Stefani19753108 @nataliagandur @urotoday @oncodaily @OncLive
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 tweet media
English
2
11
30
1.2K
CancerVisit nag-retweet
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏@CParkMD·
⭐️ The future of bladder cancer is smarter treatment for our patients. Data from KEYNOTE-B15, RETAIN, and NIAGARA at @ASCO #GU26 move us closer to rational, precision bladder preservation. ctDNA + urine tumor DNA + tumor genomics + clinical response may help identify who needs more treatment — and who can safely preserve their bladder. #BladderCancer @BladderCancerUS @WorldBladderCan @oncodaily @urotoday @OncLive
OncLive.com@OncLive

Missed the bladder cancer sessions at #GU26? @CParkMD of @Norton_Health has you covered! ✅ In the recap below, Dr Park breaks down the 2 most impactful presentations in urothelial cancer from this year's meeting: 📊-Pivotal data on perioperative EV + pembro from EV-304/KEYNOTE-B15 🧬-utDNA/ctDNA analysis of NIAGARA Watch the video to learn just why these studies are so important for practice. 🎥👇 #oncology

English
0
4
8
464
CancerVisit nag-retweet
Jame Abraham, MD, FACP
Jame Abraham, MD, FACP@jamecancerdoc·
Opportunistic salpingectomy can prevent ovarian cancer!
English
4
3
8
1.8K
CancerVisit nag-retweet
Diego A. Díaz-García
Diego A. Díaz-García@diegoadiazg·
🫁 Adjuvant Durvalumab in Resected NSCLC (BR.31). Primary population: EGFR–/ALK–, PD-L1 ≥25%. Median follow-up 60 mo. No DFS benefit: HR 0.93 (95% CI 0.71–1.25), P = .64. No benefit across hierarchical subgroups. Grade 3–4 AEs: 26% vs 20%. Adjuvant durvalumab did not improve DFS, regardless of PD-L1. 📖 @JCO_ASCO DOI 👉🏻 10.1200/JCO-25-01828 #CánCare #NSCLC #lcsm #immunotherapy #thoraciconcology
Diego A. Díaz-García tweet mediaDiego A. Díaz-García tweet mediaDiego A. Díaz-García tweet media
English
1
10
38
2.9K
CancerVisit nag-retweet
Yakup Ergün
Yakup Ergün@dr_yakupergun·
Algorithm of ET ± targeted treatment options after ET + CDK4/6 inhibitors. Some options are not yet approved— caution! From Dr. Alessandra Gennari’s excellent discussion at #ESMO25👇
Yakup Ergün tweet media
English
1
31
87
4.5K
CancerVisit nag-retweet
MV Chandrakanth
MV Chandrakanth@ChandrakanthMv·
DESTINY-Breast09 6 Facts that may surprise you The story isn’t that simple. Longer PFS than CLEOPATRA, strict stats, ~30 cycles of ADC, ILD context, pertuzumab question, CNS data pending. Game-changing? #BreastCancer #HER2 #Oncology#MVOnco
MV Chandrakanth tweet media
English
0
24
63
3.3K
CancerVisit nag-retweet
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Data from global sotorasib expanded access programs @JTOonline in KRAS G12C NSCLC (n=268). Real world PFS 6.3m, OS 9.5m, similar in PS 0-1 vs 2 and +/- brain metastases. 58% of PS2 improved to PS 0-1 after 1 cycle. Most common TRAE was diarrhea at 31%. jtocrr.org/article/S2666-…
English
0
13
31
2.4K
CancerVisit nag-retweet
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
Statin Side Effects & The "Nocebo" Effect A massive review of randomized trials found most side effects attributed to statins (memory, sleep, mood) occur just as often in placebo groups! #science #evidence @TheLancet
The Lancet@TheLancet

On the cover this week, a major meta-analysis assesses the adverse effects attributed to statin therapy in product labels. 🏷️ The study found that almost all side effects on statin labels are not caused by statins. The authors call for the labels to be updated. Read this & more: spkl.io/6015AtvkH

English
0
2
10
1.7K
CancerVisit nag-retweet
Tom Powles
Tom Powles@tompowles1·
The same applies in bladder cancer. Pathological complete response is only a potential surrogate for the effect of neoadjuvant systemic therapy on the micro-metastatic disease which is not yet radiologically visible. ctDNA tells us what’s actually happening in those micro/metastatic sites which is much more relevant.
Mali Barbi, MD MSc | Breast & Gyn Oncologist@DrBarbiOnc

Stop treating #pCR as the definitive finish line. Recent data (doi.org/10.1158/2767-9…) confirms that #ctDNA status after neoadjuvant therapy (#NAT) is a more precise prognostic indicator than #pCR. In HER2+ cohorts, patients who remained ctDNA+ after surgery were 5.5x more likely to recur, regardless of whether they achieved #pCR. The Reality Check: Prognostic vs. Predictive: We can identify high-risk patients (Prognostic), but we haven't proven yet that changing therapy based on that signal alone improves survival (Predictive). The "Low-Shedder" Floor: Especially in ER+ disease, a negative draw may just be the assay’s sensitivity limit. We can’t safely de-escalate yet. Clinical Mandate: Use ctDNA to prioritize high-risk surveillance and trial enrollment. Don’t go rogue on SOC until we have prospective utility data. #BCSM #OncTwitter #precisiononcology @SABCSSanAntonio @oncodaily

English
2
24
67
9.4K

Tuklasin

@oncodaily @MedNewsWeek @YLeyfman @GevTamamyan @YJanjigianMD @JasmineKambojMD @curijoey @drenriquegrande